Tumor-infiltrating T lymphocytes: friends or foes? (Q36381918)

13 August 2017

1 reference

title

Tumor-infiltrating T lymphocytes: friends or foes? (English)

1 reference

13 August 2017

0 references

Ping Yu

1

1 reference

13 August 2017

Yang-Xin Fu

series ordinal

2

1 reference

13 August 2017

language of work or name

English

0 references

publication date

1 March 2006

1 reference

13 August 2017

published in

Laboratory Investigation

1 reference

13 August 2017

volume

86

1 reference

13 August 2017

issue

3

1 reference

13 August 2017

page(s)

231-245

1 reference

Immunity to methylcholanthrene-induced tumours in inbred rats following atrophy and regression of the implanted tumours

13 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700389

Some further data on cytotoxic isoantibodies in the mouse

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700389

Does the immune system see tumors as foreign or self?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700389

The three Es of cancer immunoediting

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700389

A new era for cancer immunotherapy based on the genes that encode cancer antigens

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700389

Antigenic Cancer Cells Grow Progressively in Immune Hosts without Evidence for T Cell Exhaustion or Systemic Anergy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700389

Human tumor antigens recognized by T lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700389

Progress in the development of immunotherapy for the treatment of patients with cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700389

Model predicting survival in stage I melanoma based on tumor progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700389

Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700389

Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700389

Intratumor depletion of CD4+ cells unmasks tumor immunogenicity leading to the rejection of late-stage tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700389

Concomitant tumor immunity to a poorly immunogenic melanoma is prevented by regulatory T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700389

Sequential Involvement of Two Distinct CD4+ Regulatory T Cells during the Course of Transplantable Tumor Growth and Protection from 3–Methylcholanthrene‐induced Tumorigenesis by CD25–depletion

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700389

Synergism of cytotoxic T lymphocyte-associated antigen 4 blockade and depletion of CD25(+) regulatory T cells in antitumor therapy reveals alternative pathways for suppression of autoreactive cytotoxic T lymphocyte responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700389

CD4+/CD25+ regulatory cells inhibit activation of tumor-primed CD4+ T cells with IFN-gamma-dependent antiangiogenic activity, as well as long-lasting tumor immunity elicited by peptide vaccination.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700389

Identification of a CD4 binding site on the beta 2 domain of HLA-DR molecules.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700389

Substitution at residue 227 of H-2 class I molecules abrogates recognition by CD8-dependent, but not CD8-independent, cytotoxic T lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700389

Cell-mediated reaction against tumors induced by oncornaviruses. I. Kinetics and specificity of the immune response in murine sarcoma virus (MSV)-induced tumors and transplanted lymphomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700389

Antigen-driven long term-cultured T cells proliferate in vivo, distribute widely, mediate specific tumor therapy, and persist long-term as functional memory T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700389

Clonal analysis of cytotoxic T cell response against human melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700389

T-cell-mediated cytotoxicity against autologous malignant melanoma: analysis with interleukin 2-dependent T-cell cultures

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700389

Progress in human tumour immunology and immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700389

Cancer immunotherapy: moving beyond current vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700389

Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700389

Adoptive-cell-transfer therapy for the treatment of patients with cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700389

Interleukin-2 production by tumor cells bypasses T helper function in the generation of an antitumor response

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700389

Treatment of established renal cancer by tumor cells engineered to secrete interleukin-4.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700389

Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700389

Influence of interleukin 12 on p53 peptide vaccination against established Meth A sarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700389

Vaccination with cytotoxic T lymphocyte epitope-containing peptide protects against a tumor induced by human papillomavirus type 16-transformed cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700389

In vivo priming of two distinct antitumor effector populations: the role of MHC class I expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700389

Tumor immunotherapy: the tumor cell as an antigen-presenting cell

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700389

Interleukin 7 induces CD4+ T cell-dependent tumor rejection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700389

A unique tumor antigen produced by a single amino acid substitution

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700389

Point mutation in essential genes with loss or mutation of the second allele: relevance to the retention of tumor-specific antigens

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700389

Immunologically mediated regression of a murine lymphoma after treatment with anti-L3T4 antibody. A consequence of removing L3T4+ suppressor T cells from a host generating predominantly Lyt-2+ T cell-mediated immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700389

T-cell-mediated suppression of anti-tumor immunity. An explanation for progressive growth of an immunogenic tumor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700389

Generation and decay of the immune response to a progressive fibrosarcoma. II. Failure to demonstrate postexcision immunity after the onset of T cell-mediated suppression of immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700389

Tumor-specific human CD4+ regulatory T cells and their ligands: implications for immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700389

Ex vivo isolation and characterization of CD4(+)CD25(+) T cells with regulatory properties from human blood

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700389

Eradication of disseminated murine leukemia by chemoimmunotherapy with cyclophosphamide and adoptively transferred immune syngeneic Lyt-1+2- lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700389

CD4(+) T cells eliminate MHC class II-negative cancer cells in vivo by indirect effects of IFN-gamma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700389

Role of bone marrow-derived cells in presenting MHC class I-restricted tumor antigens

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700389

In vivo cross-priming of MHC class I-restricted antigens requires the TAP transporter

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700389

Complementary role of CD4+ T cells and secondary lymphoid tissues for cross-presentation of tumor antigen to CD8+ T cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700389

A conditioned dendritic cell can be a temporal bridge between a CD4+ T-helper and a T-killer cell

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700389

Ligation of CD40 on dendritic cells triggers production of high levels of interleukin-12 and enhances T cell stimulatory capacity: T-T help via APC activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700389

High level IL-12 production by murine dendritic cells: upregulation via MHC class II and CD40 molecules and downregulation by IL-4 and IL-10.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700389

CD40-independent pathways of T cell help for priming of CD8(+) cytotoxic T lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700389

T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700389

Help for cytotoxic-T-cell responses is mediated by CD40 signalling

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700389

Induction of a CD8+ cytotoxic T lymphocyte response by cross-priming requires cognate CD4+ T cell help

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700389

Virus-specific CD8(+) T cell numbers are maintained during gamma-herpesvirus reactivation in CD4-deficient mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700389

Role of dendritic cell targeting in Venezuelan equine encephalitis virus pathogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700389

Cell injury releases endogenous adjuvants that stimulate cytotoxic T cell responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700389

Peptide loading of empty major histocompatibility complex molecules on RMA-S cells allows the induction of primary cytotoxic T lymphocyte responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700389

Retrovirally transduced mouse dendritic cells require CD4+ T cell help to elicit antitumor immunity: implications for the clinical use of dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700389

Tumor-derived exosomes are a source of shared tumor rejection antigens for CTL cross-priming

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700389

Murine dendritic cells pulsed with whole tumor lysates mediate potent antitumor immune responses in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700389

Bone marrow-generated dendritic cells pulsed with a class I-restricted peptide are potent inducers of cytotoxic T lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700389

Progressive loss of CD8+ T cell-mediated control of a gamma-herpesvirus in the absence of CD4+ T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700389

Therapy of murine tumors with tumor peptide-pulsed dendritic cells: dependence on T cells, B7 costimulation, and T helper cell 1-associated cytokines

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700389

A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700389

Cooperation between cytotoxic and helper T lymphocytes in protection against lethal Sendai virus infection. Protection by T cells is MHC-restricted and MHC-regulated; a model for MHC-disease associations

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700389

Eradication of adenovirus E1-induced tumors by E1A-specific cytotoxic T lymphocytes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700389

Divergent roles for CD4+ T cells in the priming and effector/memory phases of adoptive immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700389

CD4+ T cells are required for secondary expansion and memory in CD8+ T lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700389

Requirement for CD4 T Cell Help in Generating Functional CD8 T Cell Memory

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700389

Defective CD8 T Cell Memory Following Acute Infection Without CD4 T Cell Help

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700389

CD4+ T cells are required for the maintenance, not programming, of memory CD8+ T cells after acute infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700389

Helping the CD8(+) T-cell response

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700389

Long-lasting CD8 T cell memory in the absence of CD4 T cells or B cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700389

Viral immune evasion due to persistence of activated T cells without effector function

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700389

The expanding universe of T-cell subsets: Th1, Th2 and more.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700389

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700389

Proteolysis and class I major histocompatibility complex antigen presentation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700389

Murine interleukin-4 displays potent anti-tumor activity in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700389

Distinct role of antigen-specific T helper type 1 (Th1) and Th2 cells in tumor eradication in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700389

Th1 and Th2 cell clones to a poorly immunogenic tumor antigen initiate CD8+ T cell-dependent tumor eradication in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700389

The central role of CD4(+) T cells in the antitumor immune response

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700389

Organ-specific autoimmune diseases induced in mice by elimination of T cell subset. I. Evidence for the active participation of T cells in natural self-tolerance; deficit of a T cell subset as a possible cause of autoimmune disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700389

Regulatory T cells under scrutiny

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700389

CD4+CD25+ regulatory T cells control Leishmania major persistence and immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700389

Regulatory T cells in the control of immune pathology.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700389

Naturally arising CD4+ regulatory t cells for immunologic self-tolerance and negative control of immune responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700389

CD4(+) regulatory T cells in autoimmunity and allergy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700389

Regulatory T cells in spontaneous autoimmune encephalomyelitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700389

T-regulatory 1 cells: a novel subset of CD4 T cells with immunoregulatory properties.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700389

IL-10-producing and naturally occurring CD4+ Tregs: limiting collateral damage

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700389

Regulatory T cells in the control of autoimmunity: the essential role of transforming growth factor beta and interleukin 4 in the prevention of autoimmune thyroiditis in rats by peripheral CD4(+)CD45RC- cells and CD4(+)CD8(-) thymocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700389

What is the role of regulatory T cells in transplantation tolerance?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700389

Immunologic tolerance maintained by CD25+ CD4+ regulatory T cells: their common role in controlling autoimmunity, tumor immunity, and transplantation tolerance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700389

Regulatory T cells in transplantation tolerance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700389

The immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) is caused by mutations of FOXP3

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700389

Disruption of a new forkhead/winged-helix protein, scurfin, results in the fatal lymphoproliferative disorder of the scurfy mouse

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700389

X-linked neonatal diabetes mellitus, enteropathy and endocrinopathy syndrome is the human equivalent of mouse scurfy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700389

An essential role for Scurfin in CD4+CD25+ T regulatory cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700389

Foxp3 programs the development and function of CD4+CD25+ regulatory T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700389

Control of regulatory T cell development by the transcription factor Foxp3

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700389

Induction of FoxP3 and acquisition of T regulatory activity by stimulated human CD4+CD25– T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700389

Conversion of peripheral CD4+CD25- naive T cells to CD4+CD25+ regulatory T cells by TGF-beta induction of transcription factor Foxp3

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700389

Alloantigen specific CD8+CD28- FOXP3+ T suppressor cells induce ILT3+ ILT4+ tolerogenic endothelial cells, inhibiting alloreactivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700389

Immune Enhancement of Skin Carcinogenesis by CD4+ T Cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700389

Reciprocal changes in tumor antigenicity and antigen-specific T cell function during tumor progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700389

Development and maturation of secondary lymphoid tissues.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700389

Regulation of peripheral lymph node genesis by the tumor necrosis factor family member TRANCE

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700389

LIGHT, a new member of the TNF superfamily, and lymphotoxin alpha are ligands for herpesvirus entry mediator

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700389

The requirement of membrane lymphotoxin for the presence of dendritic cells in lymphoid tissues

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700389

Lymphotoxin alpha/beta and tumor necrosis factor are required for stromal cell expression of homing chemokines in B and T cell areas of the spleen

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700389

Recombinant Human Tumor Necrosis Factor Administered as a 24-Hour Intravenous Infusion. A Phase I and Pharmacologic Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700389

The lymphotoxin-beta receptor is necessary and sufficient for LIGHT-mediated apoptosis of tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700389

Modulation of T-cell-mediated immunity in tumor and graft-versus-host disease models through the LIGHT co-stimulatory pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700389

LIGHT, a novel ligand for lymphotoxin beta receptor and TR2/HVEM induces apoptosis and suppresses in vivo tumor formation via gene transfer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700389

Human CD8+CD25+ thymocytes share phenotypic and functional features with CD4+CD25+ regulatory thymocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700389

Immunosuppressive regulatory T cells are abundant in the reactive lymphocytes of Hodgkin lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700389

ANTIGENIC SPECIFICITY OF BENZO(A)PYRENE-INDUCED SARCOMAS

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700389

7 January 2021

Depletion of CD25+ regulatory cells uncovers immune responses to shared murine tumor rejection antigens

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700389

7 January 2021

Study of tumor infiltrating lymphocytes and transforming growth factor-beta as prognostic factors in breast carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700389

7 January 2021

Flow cytometric analysis of tumour-infiltrating lymphocytes in patients with renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700389

7 January 2021

Changes on distribution of CD4+/CD45RA- and CD8+/CD11- cells in tumor-infiltrating lymphocytes of renal cell carcinoma associated with tumor progression

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700389

7 January 2021

Antigenicity of murine skin tumors induced by ultraviolet light

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700389

7 January 2021

Ultraviolet light, tumors, and suppressor T cells

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700389

7 January 2021

Melanoma cell lysis by human CTL clones: differential involvement of T3, T8 and HLA antigens

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700389

7 January 2021

The role of CD4+ T cell responses in antitumor immunity

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700389

7 January 2021

Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700389

7 January 2021

Cutting edge: Regulatory T cells from lung cancer patients directly inhibit autologous T cell proliferation

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700389

7 January 2021

IFN-gamma-dependent inhibition of tumor angiogenesis by tumor-infiltrating CD4+ T cells requires tumor responsiveness to IFN-gamma

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700389

7 January 2021

IFN-gamma can promote tumor evasion of the immune system in vivo by down-regulating cellular levels of an endogenous tumor antigen

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700389

7 January 2021

Increasing tumor antigen expression overcomes "ignorance" to solid tumors via crosspresentation by bone marrow-derived stromal cells

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700389

7 January 2021

Redundancy of direct priming and cross-priming in tumor-specific CD8+ T cell responses

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700389

7 January 2021

Induction of cytotoxic T-cell response by optimal-length peptides does not require CD4+ T-cell help

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700389

7 January 2021

Dendritic cell-based genetic immunization in mice with a recombinant adenovirus encoding murine TRP2 induces effective anti-melanoma immunity

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700389

7 January 2021

Enhanced establishment of a virus carrier state in adult CD4+ T-cell-deficient mice.

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700389

7 January 2021

CD4+ T cells are required to sustain CD8+ cytotoxic T-cell responses during chronic viral infection

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700389

7 January 2021

T Helper 1 Cytokine mRNA Is Increased in Spontaneously Regressing Primary Melanomas

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700389

7 January 2021

Cutting edge: spontaneous rejection of poorly immunogenic P1.HTR tumors by Stat6-deficient mice

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700389

7 January 2021

Cutting edge: STAT6-deficient mice have enhanced tumor immunity to primary and metastatic mammary carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700389

7 January 2021

Disregulation in TH1 and TH2 subsets of CD4+ T cells in peripheral blood of colorectal cancer patients and involvement in cancer establishment and progression

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700389

7 January 2021

CD4+ CD25+ suppressor T cells: more questions than answers

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700389

7 January 2021

Origin of regulatory T cells with known specificity for antigen

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700389

7 January 2021

Abrogation of TGFbeta signaling in T cells leads to spontaneous T cell differentiation and autoimmune disease

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700389

7 January 2021

Enhanced growth of primary tumors in cancer-prone mice after immunization against the mutant region of an inherited oncoprotein

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700389

7 January 2021

CD4+CD25+ regulatory T cells in patients with gastrointestinal malignancies: possible involvement of regulatory T cells in disease progression

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700389

7 January 2021

Targeting of lymphotoxin-alpha to the tumor elicits an efficient immune response associated with induction of peripheral lymphoid-like tissue

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700389

7 January 2021

The critical role of LIGHT, a TNF family member, in T cell development

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700389

7 January 2021

The complementation of lymphotoxin deficiency with LIGHT, a newly discovered TNF family member, for the restoration of secondary lymphoid structure and function

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700389

7 January 2021

Priming of naive T cells inside tumors leads to eradication of established tumors

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700389

7 January 2021

10.1038/LABINVEST.3700389

Identifiers

DOI

1 reference

Dimensions Publication ID

13 August 2017

1040162771

0 references

1 reference